Actively Enrolling
Diabetic Macular Edema
Oculis – DX 221
A Phase 3, Double-Masked, Randomized, Multicenter Study of the Efficacy and Safety of OCS 01 Eye Drops in Subjects with Diabetic Macular Edema
Eyebiotech, Ltd EYE-RES-102
EYE-RES-102 is a randomized, double masked pivotal study to evaluate the efficacy and safety of 2 dose levels of EYE103 in comparison with the active control, ranibizumab, in patients with diabetic macular edema (DME)
Intermediate Age-Related Macular Degeneration (iAMD)
Genentech – GE43220
A Multicenter, Prospective, Observational Study of the Progression of Intermediate Age-Related Macular Degeneration
Macular Telangiectasia
The Lowy Medical Research Institute – NHOR
A Natural History Observation and Registry Study of Macular Telangiectasia Type-2
Wet AMD
Outlook Therapeutics – ONS-5010
A Phase 3, 3-Month Study to Assess the Safety and Effectiveness of ONS-5010 Compared to Lucentis in Subjects with Neovascular Age-related Macular Degeneration: NORSE EIGHT
Ocular Therapeutix – OTX-TKI-2023-AMD-301
Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (axitinib implant) in Subjects with Neovascular Age-Related Macular Degeneration: SOLEIL/SOL 1
Ocular Therapeutix – OTX-TKI-2023-AMD-303
A Phase 1/2 Dose-Escalation and Randomized, Controlled, Masked Expansion Trial in Adults with wet AMD Undergoing Active Anti-VEGF Treatment
4D Molecular Therapy – 4D-150
A Phase 1/2 Dose-Escalation and Randomized, Controlled, Masked Expansion Trial in Adults with wet AMD Undergoing Active Anti-VEGF Treatment
Kalaris Therapeutics, Inc KLRS-100
A Phase 1 Open-label Clinical Trial to Establish the Safety, Tolerability, Dose-Range and Pharmacokinetic Profile of Intravitreal Injection of TH103 in Patients with Neovascular Age Related Macular Degeneration
DME & Wet AMD
Regeneron VGFTe-HD-OD-2444
A Phase 3B Single-Arm Study of Aflibercept 8 mg in Participants with Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME)
Contact Information
If you are interested in learning more about these clinical trials, please contact our offices at (803) 931-0077